Extracellular expression of TROP2 has been found to correlate with poor prognosis in other cancers including breast [19], gastric [20] as well as gliomas [21], suggesting that TROP may also represent a functional marker for cell sub-populations with enhanced ability to avoid cell death and/or to recover from treatment in these cancers. Here, TACSTD2 is linked to central nervous system cancer.